Min Chu, Ph.D.
Chief Scientific Officer/Director of Pharmaceutical Chemistry
Dr. Chu’s extensive career in drug development and analytical chemistry includes nearly 30 years in the biopharmaceutical and biotechnology industries and over two decades at two of the world’s largest pharmaceutical companies. His scientific accomplishments in research and development are evidenced in over 110 patents, publications, scientific presentations, and invited lectures. Well-versed in GLPs and cGMPs, Dr. Chu was most recently Vice President of Research and Development at Unigen, where he led multidisciplinary teams for discovery, development, and commercial launch of new dietary supplement products in joint pain relief and protection, weight loss, and skin care. Previously, he was Director of Bioanalytical and Natural Products Chemistry for Cubist Pharmaceuticals (NASDAQ: CBST), which was subsequently acquired by Merck & Co. in an $8.4 billion transaction, where his responsibilities spanned discovery of novel antibiotics against resistant strains or “superbugs,” advancing drug candidates to preclinical and clinical development, and laboratory design and development.
Prior to that, Dr. Chu spent 16 years in various roles at Schering-Plough Research Institute (now Merck), including Senior Scientist, Principal/Senior Principal Scientist, and Research Fellow, working on isolation and identification of biologically active compounds from natural sources, including plant and marine species and microorganisms, as potential candidates for drug development. Chu’s scientific interests included discovery and development of bioactive natural products from herbal plants and microbial and marine species for medicinal use in various therapeutic areas including cancer, cardiovascular, CNS and infectious diseases. Dr. Chu earned his Ph.D. degree in Organic Chemistry from the State University of New York at Stony Brook. He conducted his postdoctoral research of plant natural products-terpenoids synthesis in University of Illinois at Urbana-Champaign.